406 related articles for article (PubMed ID: 14723611)
1. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy.
Dubois RW; Melmed GY; Henning JM; Laine L
Aliment Pharmacol Ther; 2004 Jan; 19(2):197-208. PubMed ID: 14723611
[TBL] [Abstract][Full Text] [Related]
2. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.
Chan FK; Graham DY
Aliment Pharmacol Ther; 2004 May; 19(10):1051-61. PubMed ID: 15142194
[TBL] [Abstract][Full Text] [Related]
3. Review article: appropriate use of proton pump inhibitors with traditional nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors.
Kimmey MB; Lanas A
Aliment Pharmacol Ther; 2004 Feb; 19 Suppl 1():60-5. PubMed ID: 14725581
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review.
Hooper L; Brown TJ; Elliott R; Payne K; Roberts C; Symmons D
BMJ; 2004 Oct; 329(7472):948. PubMed ID: 15475342
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.
Latimer N; Lord J; Grant RL; O'Mahony R; Dickson J; Conaghan PG;
BMJ; 2009 Jul; 339():b2538. PubMed ID: 19602530
[TBL] [Abstract][Full Text] [Related]
6. Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis.
Ofman JJ; Badamgarav E; Henning JM; Knight K; Laine L
Am J Med; 2004 Jun; 116(12):835-42. PubMed ID: 15178499
[TBL] [Abstract][Full Text] [Related]
7. Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors.
Micklewright R; Lane S; Linley W; McQuade C; Thompson F; Maskrey N
Aliment Pharmacol Ther; 2003 Feb; 17(3):321-32. PubMed ID: 12562444
[TBL] [Abstract][Full Text] [Related]
8. Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs.
Naesdal J; Wilson I
Eur J Gastroenterol Hepatol; 2001 Dec; 13(12):1401-6. PubMed ID: 11742186
[TBL] [Abstract][Full Text] [Related]
9. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
Scheiman JM; Hindley CE
Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
[TBL] [Abstract][Full Text] [Related]
10. Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents.
You JH; Lee KK; Chan TY; Lau WH; Chan FK
Aliment Pharmacol Ther; 2002 Dec; 16(12):2089-96. PubMed ID: 12452942
[TBL] [Abstract][Full Text] [Related]
11. Non-steroidal anti-inflammatory drug toxicity in the upper gastrointestinal tract.
Sung J; Russell RI; Nyeomans ; Chan FK; Chen S; Fock K; Goh KL; Kullavanijaya P; Kimura K; Lau C; Louw J; Sollano J; Triadiafalopulos G; Xiao S; Brooks P
J Gastroenterol Hepatol; 2000 Oct; 15 Suppl():G58-68. PubMed ID: 11100995
[TBL] [Abstract][Full Text] [Related]
12. Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs.
Scheiman JM; Fendrick AM
Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S23-9. PubMed ID: 16168078
[TBL] [Abstract][Full Text] [Related]
13. COX-2-specific inhibitor or proton pump inhibitor plus traditional NSAID: is either approach sufficient for patients at highest risk of NSAID-induced ulcers?
Cryer B
Gastroenterology; 2004 Oct; 127(4):1256-8. PubMed ID: 15481002
[No Abstract] [Full Text] [Related]
14. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
[TBL] [Abstract][Full Text] [Related]
15. Selective cyclo-oxygenase-2 inhibitors: cardiovascular and gastrointestinal toxicity.
Wallace JL; Muscará MN
Dig Liver Dis; 2001 Dec; 33 Suppl 2():S21-8. PubMed ID: 11827359
[TBL] [Abstract][Full Text] [Related]
16. NSAIDs: gastroprotection or selective COX-2 inhibitor?
Dickman A; Ellershaw J
Palliat Med; 2004 May; 18(4):275-86. PubMed ID: 15198117
[TBL] [Abstract][Full Text] [Related]
17. COX-2 inhibitors. What is their place?
McGettigan P
Aust Fam Physician; 2000 Sep; 29(9):847-52. PubMed ID: 11008387
[TBL] [Abstract][Full Text] [Related]
18. Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract.
James MW; Hawkey CJ
Br J Clin Pharmacol; 2003 Aug; 56(2):146-55. PubMed ID: 12895187
[TBL] [Abstract][Full Text] [Related]
19. Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?
Savage R
Drugs Aging; 2005; 22(3):185-200. PubMed ID: 15813652
[TBL] [Abstract][Full Text] [Related]
20. An evidence-based approach to the gastrointestinal safety profile of COX-2-selective anti-inflammatories.
Schoenfeld P
Gastroenterol Clin North Am; 2001 Dec; 30(4):1027-44, viii-ix. PubMed ID: 11764531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
